Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 11Stomach Neoplasms 10Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 5Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1High-risk Non-muscle Invasive Bladder Cancer 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Biliary Tract Neoplasms 1

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1trastuzumab deruxtecan 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × HER2-positive Gastric Cancer × disitamab vedotin × Clear all
NCT05586061 2025-02-07

RCTS

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
55 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡